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Antigen-antibody complexes play an important role in the
activation of the innate and adaptive immune system and thus in
host defense against infectious agents and cancer as well as in
immune-mediated diseases such as allergy and autoimmunity.1
The most common immune complex–mediated hypersensitivity
disease is IgE-associated allergy, which affects more than 25%
of the population.2 Allergic patients suffer from various
symptoms such as hay fever, food allergy, dermatitis, severe
and disabling asthma, and life-threatening anaphylactic shock.3
Atopic individuals are genetically predisposed to develop IgE
antibodies upon contact with per se harmless antigens (ie, aller-
gens), whereas healthy persons mount IgG antibody responses.4
After sensitization, IgE antibodies bind with high affinity to
receptors (ie, FcεRI) on immune cells (eg, mast cells, basophils,
antigen-presenting cells, and eosinophils).5,6 Subsequent allergen
contact cross-links allergen-specific IgE antibodies on effector
cells (eg, mast cells and basophils) leading to the immediate
release of biological mediators (eg, histamine and leukotrienes)
responsible for acute allergic inflammation.7,8
As early as 1924, Karl Landsteiner9 had demonstrated that poly-
valent antigen is required to trigger an allergic reaction, whereas
monovalent antigen (ie, hapten) failed to do so and even induced
a state of ‘‘antianaphylaxis.’’ An in vitro system in which cultured
basophils are stimulated with allergen to release histamine was
developed byLichtenstein andOsler10 tomimic immediate allergic
inflammation. Using this system, it is possible to define factors that
determine the magnitude of effector cell activation.
Using chemically cross-linked IgE or anti-IgE antibodies, it has
been shown that cross-linking of IgE antibodies requires at least 2
IgE epitopes on an allergen molecule for the activation of effector
cells.11-14 However, the in-depth analysis of IgE-allergen
complex formation and effector cell activation has been hampered
by the lack of defined molecular tools. In the last 2 decades, the
molecular structures of most of the allergens with relevance for
human allergy have been revealed.15 Using a peptide epitope of
one of the most important respiratory allergens (ie, Phl p 1 from
timothy grass pollen) and a corresponding monoclonal IgE
antibody, we demonstrated that the extent of effector cell
degranulation depends not only on the levels of allergen-
specific IgE antibodies but also on the number of IgE epitopes.16
The molecular analysis of several allergens important for human
allergy has indicated that they contain several different IgE
binding sites. It has been speculated that they can appear in
clusters on allergen surfaces.17-24 These observations led us to
hypothesize that the proximity of IgE binding sites on an allergen1557
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effector cell degranulation, and thus to determine its allergenic
potency.
To investigate whether the proximity of IgE binding sites on an
allergen is important for its allergenic activity, we grafted an IgE
epitope from the major timothy grass pollen allergen, Phl p 1, in
different numbers and proximity onto a per se nonallergenic
molecule, that is, horse heart myoglobin. Using negative-stain
electron microscopy (EM), we studied the shapes of immune
complexes formed between the artificial allergens and the
corresponding IgE antibodies. When the same epitopes were
placed in adjacent proximity on the surface of the artificial
allergen, immune complexes with a closed shape (ie, compact
ring shape) dominated whereas open complexes in the form of
short chains were observed when epitopes were placed on
different ends and proximity of the host molecule. Importantly,
allergen constructs containing the same epitopes engineered
into adjacent positions were more potent in inducing degranula-
tion of basophils loaded with IgE and allergic inflammation in
mice, which had been sensitized with IgE, than were constructs
containing distantly placed epitopes. Our results thus demonstrate
that the proximity of epitopes on a given antigen profoundly
affects the shape of the resulting antigen-antibody immune
complexes and the potency of the antigen to activate immune cells
via these immune complexes.
METHODS
Materials and reagents
Purified rPhl p 1 was purchased from BIOMAY AG (Vienna, Austria).
Myoglobin from equine heart was obtained from Sigma-Aldrich (Vienna,
Austria). The mouse monoclonal IgE antibody against the Phl p 1–derived
peptide P1 (EPVVVHITDDNEEPIAPYHFDLSGHAFGAMA, aa 86-116)
was obtained by immunizing BALB/c mice with the KLH-coupled peptide as
described previously.16,25
Construction, expression, and purification of
myoglobin derivatives
cDNAs coding for the His-tagged myoglobin derivatives (MB1N, MB2N,
MB1N1aa46-47, MB1N1C, MB2N1C, and MB4N) were obtained as
synthetic genes with a codon usage optimized for expression in Escherichia
coli (ATG-Biosynthetics GmbH, Merzhausen, Germany) and were subcloned
into the NdeI/EcoRI sites of the plasmid pET17b.
The recombinant proteins were expressed in E coli strain BL21 (DE3)
(Stratagene, East Key, Australia), which was grown in lysogeny broth medium
supplemented with 100mg/L ampicillin. Protein expression was induced at an
OD600 of 0.6 by the addition of 0.5 mM isopropyl-b-thiogalactopyranoside.
After culturing for 2 to 4 hours, cells were harvested by centrifugation
(37,500 3 g, 15 minutes, 48C), resuspended in 6 mol/L guanidium
hydrochloride, 100 mMNaH2PO4, and 10 mM Tris (pH 8), and homogenized
for 1 minute at room temperature (Ultra-turrax; IKA, Staufen, Germany). The
bacterial cell lysates were centrifuged (45,0003 g, 20 minutes, 48C), and the
recombinant protein-containing supernatants were purified using Ni-NTA
affinity columns (Qiagen, Hilden, Germany). Protein preparations were
dialyzed in 10 mM NaH2PO4, pH 8.0, and checked for purity by Coomassie
Brilliant Blue staining of 14% SDS polyacrylamide gels (SDS-PAGE), andthe protein concentrations were determined by Micro-BCA Protein Assay
Kit (Pierce, Rockford, Ill).
SDS-PAGE
Myoglobin derivativeswere analyzedbymeans ofSDS-PAGEunder reducing
as well as nonreducing, conditions.26 Reducing conditions were obtained by dis-
solving the proteins in sample buffer containing 70 mmol/L b-mercaptoethanol.
After boiling, 5-mg aliquots of each protein were separated in 14% SDS-PAGE.
Gels were subsequently stained with Coomassie Brilliant Blue.
Circular dichroism analysis
Circular dichroism (CD) spectroscopy was performed on a JASCO J-810
spectropolarimeter (Japan Spectroscopic Co, Tokyo, Japan). Spectra
were recorded from 195 to 260 nm with 0.5 nm resolution at a scan speed
of 50 nm/min using a 0.2-cm quartz cuvette and resulted from averaging
3 scans. All measurements were performed in 10mMphosphate buffer (pH 8).
The final spectra were baseline-corrected by subtracting the corresponding
buffer spectra obtained under identical conditions. Results were expressed as
the mean residue ellipticity [Ө] at a given wavelength.
Gel filtration
Gel filtration of myoglobin derivatives was performed in 20 mM sodium
phosphate, pH 7.6, and 150 mM sodium chloride buffer at a flow rate of
0.3 mL/min. Fifty microliter of each sample was loaded onto the Superose6
FPLC column (Pharmacia Biotech, GE Healthcare, Uppsala Sweden) and
detected at 280 nm. The column was calibrated with bovine thyroglobulin
(670 kDa), bovine g-globulin (158 kDa), chicken ovalbumin (44 kDa), horse
myoglobin (17 kDa), and vitaminB12 (1.35 kDa) (BIO-RAD,Hercules, Calif).
Quantitative IgE reactivity as determined by
binding to dot-blotted purified myoglobin
derivatives
Reactivities of recombinant myoglobin derivatives and the Phl p 1–specific
monoclonal IgE were determined by dot blot experiments. For this purpose,
different concentrations (2.5, 5, 10 nM/mL) of myoglobin derivatives and
horse heart myoglobin, as a control protein, were dotted in 2-mL aliquots onto
nitrocellulose membrane strips (Schleicher & Schuell, Dassel, Germany). The
strips were blocked with buffer A (40 mM Na2HPO4, 0.6 mM NaH2PO4, pH
7.5, 0.5% Tween 20, 0.5% [w/v] BSA) and exposed overnight to 1 mL of the
Phl p 1–specific monoclonal IgE diluted 1:10 in buffer A (75 pM/mL). Bound
IgE antibodies were detected with a 125I-labeled antimouse IgE antibody
(200,000 cpm/mL), visualized by autoradiography using KODAK X-OMAT
films and intensifying screens (Kodak, Heidelberg, Germany),27 and quanti-
fied using a gamma counter (Wizzard Automatic Gamma Counter; Wallac,
Turku, Finland). The Mann-Whitney U test was used for statistical analysis
(GraphPad Prism software; GraphPad, San Diego, Calif).Negative-stain EM
Negative-stainEMwas performedas previously described.28Briefly, IgE and
purified soluble myoglobin derivatives at 0.5 to 1.0 mg/mLwere diluted in buff-
ered saline borate to a final concentration of 5 to 10mg/mL and affixed to carbon
membrane supports for assessment of molecular homogeneity. The membranes
were stainedwith 1%uranyl formate andmounted on 600-mesh copper grids for
analysis. Electron micrographs were recorded at 100,000 3 magnification at
100 kV on a JEOL JEM-1200 electron microscope. To generate molecular
complexes, the reactants were mixed at an approximately 1:1 molar ratio
(0.5mg/mL IgE and 0.05mg/mLmyoglobin construct, unless otherwise stated)
for 30minutes at room temperature and diluted 20-fold in buffered saline borate
just before attachment to carbon membranes. Following EM analysis, the ratios
of the reactantswere sometimes adjusted tomaximize the ratio of the complexes
to unreacted molecules or to saturate constructs with IgE (ie, antibody excess).
Representative electron micrographs of the antigen-antibody mixtures were
digitized and manually scored for the presence and morphology of the resulting
cross-linked immune complexes.
A B
FIG 1. Conversion of horse heart myoglobin into an IgE-reactive protein. A, Schematic overview of
myoglobin derivatives (MB1N, MB2N, MB1N1aa46-47, MB1N1C, MB2N1C, and MB4N) containing 1 to 4
identical copies of an IgE-reactive peptide (orange) in different proximity in the myoglobin sequence
(arrows). Spacers and hexahistidine tags are indicated with gray and yellow, respectively. B, Ribbon and
space-fill representations of the 3-dimensional structure of horse heart myoglobin showing the positions
of the 3 N-terminal (blue) and 4 C-terminal amino acids (red) as well as of amino acids 46 and 47 (green).
Fig 1, B, was made with the MacPyMOL Molecular Graphics System using PDB coordinate file 1wla.
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Rat basophil leukemia (RBL)-2H3 cells29 were passively sensitized with
different dilutions (1:500, 1:5000) of Phl p 1–specific monoclonal IgE
antibody. After washing, cells were stimulated by adding serial dilutions
(0.001-102.4 nM/mL) of recombinant myoglobin derivatives. In order to
measure spontaneous release, RBL cells were passively sensitized without
further allergen challenge (controls). Mediator release was quantified by
measuring b-hexosaminidase, and results are reported as the percentage of to-
tal b-hexosaminidase, obtained by lysing cells with Triton X-100 (Merck,
Darmstadt, Germany). All measurements were performed in duplicate.16
BIAcore analysis
BIAcore data acquisition and analysis are detailed in theMethods section in
this article’s Online Repository available at www.jacionline.org.
Passive anaphylaxis model
BALB/cmice (n5 4/group)were injected intravenouslywitheither80mg (4-
mg dose experiment) or 96.8 mg (40-mg dose experiment) of peptide-specific
monoclonal IgE antibody followed 10 hours later by intravenous challengewith
either 4 mg or 40 mg of myoglobin derivatives. The severity of the anaphylactic
shock was assessed by decrease in rectal temperature.30RESULTS
Construction of artificial allergens containing
defined numbers of IgE epitopes in different
proximity
For the construction of artificial allergens, the myoglobin
molecule was chosen as a host molecule because it is a strictly
monomeric protein with a molecular weight of 17.6 kDa, which is
in the range of typical allergens.Myoglobin consists of 153 amino
acids and is organized into 8 a-helical regions (A, aa 3-18; B, aa
20-35; C, aa 36-42; D, aa 51-57; E, aa 58-77; F, aa 86-95; G, aa
100-118; H, aa 124-149) (Fig 1).31
The IgE-reactive Phl p 1 peptide, comprising 11 amino acids
(DLSGHAFGAMA),16was grafted on theN-terminus aswell as the
C-terminus and in the loop region between aa 46-47 of myoglobin
(Fig 1, A). We engineered and purified 6 recombinant myoglobin
derivatives, each containing 1 to 4 identical IgE-reactive peptides
and a C-terminal His-tag to facilitate purification (Fig 1, A).
Fig 1, A, shows a schematic overview of the myoglobin
derivatives, and Tables E1 and E2 in this article’s Online
Repository available at www.jacionline.org display their
FIG 2. Coomassie-stained SDS-PAGE gels showing the mobility of purified myoglobin derivatives (lanes
1-6: MB1N, MB2N, MB1N1aa46-47, MB1N1C, MB2N1C, MB4N) separated under nonreducing (A) and
reducing (B) conditions. Molecular weights (kDa) are displayed. C, Monomeric behavior of the myoglobin
derivatives demonstrated by gel filtration (x-axis: elution volumes in mL; y-axis: milli absorbance units at
280 nm). Arrows indicate peaks of protein standards (thyroglobulin, 670 kDa; bovine gamma globulin,
158 kDa; chicken ovalbumin, 44 kDa; equine myoglobulin, 17 kDa; vitamin B12, 1.35 kDa). D, Far ultraviolet
CD analysis showing mean residue ellipticities (Ө, y-axis) of purified myoglobin and myoglobin derivatives
recorded at different wavelengths (x-axis).
TABLE I. IgE reactivity of myoglobin derivatives
Antigens
cpm 6 SD
2.5 nM/mL 5 nM/mL 10 nM/mL
MB1N 116.5 6 18.5 374.0 6 37.4 933.6 6 134.5
MB2N 266.3 6 118.2 651.1 6 53.9 2294.6 6 961.9
MB1N1aa46-47 199.4 6 24 433.3 6 146.3 1579.7 6 259.0
MB1N1C 232 6 42.4 526.0 6 69.7 1253.3 6 394.6
MB2N1C 776.4 6 104.9 1267.9 6 50.8 2583.8 6 113.5
MB4N 2217.9 6 63.6 3112.5 6 155.8 5437.1 6 47.2
Myoglobin 37.4 6 8.31 43.8 6 9.6 57.4 6 9.7
Nitrocellulose-dotted aliquots (2 mL) of myoglobin or myoglobin derivatives (2.5 nM/
mL, 5 nM/mL, 10 nM/mL) were exposed to the monoclonal IgE antibody and bound
IgE was detected with 125I-labeled anti-IgE and quantified by gamma counting.
Results are displayed in counts per minute (cpm).
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MB2N, and MB4N contain 1, 2, or 4 copies of the IgE binding
site on the N-terminus, respectively. MB1N1C and MB2N1C,
respectively, contain 1 or 2 IgE binding sites on the N-terminus
plus 1 at the C-terminus, whereas MB1N1aa46-47 has one IgE
binding site on the N-terminus and the second in the loop
region between aa 46-47. The rationale behind the grafting of
the IgE binding sites was 2-fold. To test for the effect of multiple
epitopes in close proximity to one another, 2 or 4 IgE epitopes
were placed on the N-terminus of myoglobin separated from
one another only by small flexible spacers consisting of 6 glycine
residues.To test for the effects of epitopes grafted into fixed positions at
defined distances and orientations with respect to one another,
IgE-reactive peptides were grafted to the N-terminus and the
C-terminus of myoglobin or in the loop region at aa 46-47, which
according to the atomic model should place it at a specific
distance and position from both the N- and C-termini (Fig 1, B).
Fig 2, A, shows the purity of the purified recombinant
myoglobin derivatives and confirms their predicted molecular
masses, which were also determined by mass spectrometry
(data not shown). Also, under nonreducing conditions
purified myoglobin derivatives migrated as monomeric bands in
SDS-PAGE (Fig 2, B) and appeared monomeric in the fluid phase
as demonstrated by gel filtration (Fig 2, C).
CD analysis of the recombinant myoglobin derivatives showed
that they contain considerable secondary structure consisting
mainly of a-helices, which is very similar to that of myoglobin.
The CD spectra are characterized by minima at 208 nm and
222 nm and a maximum at 195 nm (Fig 2, D).IgE reactivity of artificial allergens and formation of
immune complexes of different shapes depend on
the proximity and the number of epitopes
To determine the IgE-binding capacity of the recombinant
myoglobin derivatives, a quantitative radioallergosorbent test–
based IgE binding test was performed with equimolar amounts of
purified dot-blotted nondenatured proteins. The results presented
FIG 3. Visualization of complexes consisting of myoglobin derivatives and bound IgE antibodies by
negative-stain EM. Representative micrographs and interpretive diagrams showing complexes of IgE with
MB1N (A), MB2N (B), MB1N1aa46-47 (C), MB1N1C (D), MB2N1C (E), and MB4N (F). Bars represent 50 nm.
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according to the number of grafted epitopes.
To visualize IgE binding to the derivatives and the resulting
immune complexes, negative-stain EM was performed.28 When
monovalent MB1N and IgE antibodies were mixed, mostly
monomeric IgE was visible (Fig 3, A). Because of the small
size of MB1N (18,833 kDa), IgE-associated MB1N molecules
could not be reliably detected though some Fab arms did appear
to have additional protein mass at the distal tip (Fig 3, A, arrows
in enlargement). In contrast, mixtures of the di- or polyvalent
derivatives with IgE resulted in the formation of various types
of immune complexes (Fig 3, B-F; see Tables E3 and E4 and
Fig E1, A-E, in this article’s Online Repository available at
www.jacionline.org). In all cases, a considerable percentage
(29.2% to 92.5%) of bound IgEs were in large complexes (ie,
containing >_4 IgE members). Interestingly, immune complexes
with a closed shape (ie, compact ring shape) were most abundant
in mixtures containing the constructs with 2 adjacent IgE binding
sites located at the N-terminus (ie, 23.6% for MB2N, 17.2% for
MB2N1C) (Fig 3, B and E; see Table E4 and Fig E1, A and D)
as compared to other constructs with 2 epitopes in more distant
proximity (ie, 3.1% for MB1N1aa46-7, 3.8% for MB1N1C).
These data indicate that despite the close proximity of theMB2N epitopes, the 6xGly linker must allow them to orient in
such a way as to minimize steric clashes between the bound
IgE Fab arms. In the absence of steric restrictions, rings composed
of 2 IgE antibodies and 2 divalent antigens are the energetically
most favored form of immune complexes.32 Short chains and
larger ringswere also observed in both preparations. Interestingly,
the MB2N1C construct, which has an additional epitope ap-
pended to the C-terminal end of myoglobin, gave an immune
complex distribution with somewhat fewer ring dimers (17.2%)
and a greater number of large (average, 11.7 IgEmolecules) com-
plexes as compared to MB2N, suggesting that even though the C-
terminal epitope played little role in ring formation (Fig 3, E; see
Fig E1, D), it does contribute to cross-linking. This perception
was reinforced by results obtained from EM analysis of the
MB1N1C 1 IgE mixture (Fig 3, D; see Fig E1, C) where only
3.8% of the complexes were dimer rings (see Table E4). For
MB1N1C, most of the nonring complexes were composed of
just 2 (60.5%) or 3 (23.6%) IgE members and this construct
formed the fewest large complexes (see Table E4), suggesting
that the C-terminal epitope was less likely than the N-terminal
epitopes to participate in the binding necessary for extensive
cross-linking. These data were unexpected because the atomic
modeling suggests that the distance between the N- and C-
FIG 4. Allergenic activity of myoglobin derivatives analyzed in vitro by RBL mediator release assays and in
a murine model of passive anaphylaxis. A and B, RBL cells were loaded with different dilutions (Fig 4, A,
1:500; Fig 4, B, 1:5000) of the peptide-specific monoclonal IgE antibody and stimulated with increasing
concentrations (0.001-100 nM/mL) of myoglobin and the myoglobin derivatives (x-axes). C, Detailed
analysis of basophil degranulation by myoglobin derivatives containing 2 IgE epitopes in different
proximity. b-hexosaminidase release is displayed as percentage of total release on the y-axis (SDs: error
bars). D and E, BALB/c mice (n 5 4/group) were primed with peptide-specific monoclonal IgE antibody
and challenged 10 hours later with either (Fig 4, D) 4 mg or (Fig 4, E) 40 mg of myoglobin derivatives. Rectal
temperatures were determined every 5 minutes for the next 1 hour.
J ALLERGY CLIN IMMUNOL
MAY 2016
1562 GIERAS ET ALterminal epitopes would eliminate steric restrictions and the
angular orientation of the epitopes should foster cross-linking
and ring formation (Fig 1, B). Empirical adjustments to the ratio
of antibody to antigen did not lead to enhanced binding or cross-
linking (data not shown).
Together with the MB2N1C results described above, we
speculate that molecules with epitopes at the N- and C-termini
present them to IgE in a configuration that is not conductive to
compact ring formation.
Like MB1N1C, MB1N1aa46-47 has 1 N-terminal epitope and
1 additional epitope between aa 46-47 (Fig 1, A), a configuration
that should foster cross-linking and small ring formation.
However, as with MB1N1C, we saw little evidence of ring
formation (3.1%), extensive small 2-member (57.9%) and
3-member (25.6%) linear complexes and rather few (13.4%) largecomplexes (Fig 3, C; see Table E4 and Fig E1, B). Clearly, the
presence of 2 epitopes, per se, is not driving the type of complexes
formed (compare MB2N with 23.6% of 2 IgE member rings to
MB1N1aa46-47 [3.1% rings] and MB1N1C [3.8% rings]; see
Table E4). Rather, it is most likely that the relative positions
and/or accessibility are driving the differences in formation of im-
mune complexes.
A wide variety of immune complexes containing rings
(typically rings of 4 rather than 2), chains, and various
combinations of both were observed for MB4N, the derivative
containing 4 epitopes at the N-terminus (Fig 3, F; see Table E4
and Fig E1, E). Many of the complexes were quite large (average,
17.1 IgE molecules) as compared to those for MB1N1C (average,
7.0 IgE molecules) and MB1N1aa46-47 (average, 8.3 IgE
molecules). Such higher order complexes are to be expected if
J ALLERGY CLIN IMMUNOL
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the multiple components and crowded architecture of many of the
complexes, the actual functional valency of MB4N was difficult
to assess when the reactants were incubated at equivalence. To
address this issue, we incubated some samples at a 4-fold IgE
molar excess in an attempt to saturate the epitopes and minimize
cross-linking potential. Many more examples of 3 and 4 IgE
antibodies each with one arm converging on a central focal point
(the presumed location of MB4N) were observed, mostly within
larger immune complexes. However, clear examples of 3 and 4
isolated IgE antibodies with Fab arms bound to a single focus
were observed (Fig 3, F, bottom row). Thus, the 3 6xGly linkers
appear to provide sufficient flexibility and spacing to allow
simultaneous IgE binding to all 4 N-terminal epitopes.Molecules containing IgE epitopes engineered into
adjacent positions are more potent at inducing
basophil degranulation than are molecules with
distantly placed epitopes
In an attempt to correlate the atomic modeling and EM-derived
structural information with functional IgE-mediated basophil
triggering, we next compared the allergenic activity of various
myoglobin derivatives in vitro using the RBL cell model.29
Cultured RBL-2H3 cells were loaded with monoclonal IgE
antibodies, exposed to the myoglobin derivatives, and assayed
for b-hexosaminidase release (Fig 4, A-C).
When RBL cells were incubated with monovalent MB1N, no
relevant mediator release could be detected (Fig 4, A). Because
MB1N reacted with the monoclonal IgE antibody (Table I), this
result can be explained by monovalent, hapten-like IgE binding
without induction of cross-linking of FcεRI-bound IgE
antibodies16 and is consistent with the paucity of immune com-
plexes observed by EM. Among the other myoglobin derivatives,
MB4N, the construct with the largest and most abundant soluble
immune complexes, was the most potent inducer of degranulation
(Fig 4,A). It inducedmediator release at an allergen concentration
as low as 0.01 nM/mL. Next most potent were MB2N and
MB2N1C, and both these constructs yielded similar soluble
complexes consisting of rings and chains. Interestingly, the
divalent MB1N1C and MB1N1aa46-47 bound approximately
the same amount of IgE as MB2N (Table I) but showed much
lower allergenic activity than did MB2N (Fig 4, A). These results
are in general agreement with the EM data, which showed far
fewer complexes for the MB1N1aa46-47 and MB1N1C
constructs than for MB2N (Fig 3, B-D; see Fig E1, A-C). When
RBL cells were loaded with a 10-fold lower concentration of
the monoclonal IgE but challenged with the same concentration
of derivatives, the maximal percentage of mediator release was
reduced considerably (Fig 4, B).
The relative allergenic potencies of the different myoglobin
derivatives were not changed when cells were loaded with lower
amounts of IgE (Fig 4, B). MB4N was again the most allergenic
protein followed by MB2N and MB2N1C. Again, MB1N1C
and MB1N1aa46-47 were the proteins with the lowest allergenic
activity. We then tested the allergenic activity of the 3 divalent
constructs, MB2N, MB1N1C, and MB1N1aa46-47, in detail by
using 1:2 dilutions of the purified proteins (0.05-102.4 nM/mL)
and again found that almost 10-fold less MB2N was needed to
induce the same amount of basophil activation as was achieved
with MB1N1aa46-47 (Fig 4, C). The in vitro allergenic activityof MB1N1C was reproducibly lower than that of MB2N but
higher than that of MB1N1aa46-47 (Fig 4, C). However,
MB2N, MB1N1C, and MB1N1aa46-47 contain exactly the
same number of IgE epitopes and appear to bind approximately
the same number of IgE antibodies (no statistical difference)
with comparable association and dissociation profiles (Table I;
see Fig E2 in this article’s Online Repository available at www.
jacionline.org). The EM and basophil results therefore indicate
that the proximity of an allergen’s IgE epitope has an effect on
its ability to cross-link IgE antibodies on effector cells.Allergen molecules with IgE epitopes engineered
into adjacent positions show high allergenic
activity in sensitized mice
We next studied the in vivo allergenic activity of those
derivatives giving different results in in vitro basophil
degranulation experiments in a murine model of anaphylaxis.30
Mice were primed by injection with the monoclonal IgE and
then challenged with 2 different doses (4 mg or 40 mg/mouse)
of the individual derivatives (MB1N, MB2N, MB1N1aa46-47,
MB1N1C, MB4N) and myoglobin as negative control. No
relevant temperature drop indicative of a systemic anaphylactic
reaction was observed with myoglobin or the MB1N derivative
that contained only 1 IgE binding site (Fig 4, D and E). Mice
receiving low-dose myoglobin derivatives showed no decrease
in body temperaturewithMB1N andMB1N1aa46-47, amoderate
decrease with MB2N and MB1N1C, and a substantial
temperature drop within 20 minutes of injection of MB4N (Fig
4, D). Increasing the allergen dose to 40 mg led to a considerable
temperature drop in mice receiving derivatives containing 2 or
more IgE binding sites; again, this was most pronounced with
MB4N (Fig 4, E). In contrast, no statistically significant
differences were observed regarding the induction of peptide-
and Phl p 1–specific IgE and IgG1 antibody levels when mice
were sensitized with the myoglobin derivatives (MB1N, MB2N,
MB1N1aa46-47, MB1N1C, MB2N1C, MB4N) (see Fig E3,
A-F, in this article’s Online Repository available at www.
jacionline.org). Airway hyperresponsiveness in murine models
is mediated mainly by allergen-specific T-cell responses but not
by IgE-mediated mast cell or basophil activation.33 Because the
constructs did not contain grass pollen allergen-specific T-cell
epitopes recognized by BALB/c mice, we found no airway
hyperresponsiveness toward Phl p 1 in mice sensitized with the
constructs (data not shown).DISCUSSION
We have shown in a molecular approach with defined reagents
that the proximity of epitopes on a given allergen determines the
shape of immune complexes consisting of the allergen and the
corresponding IgE antibodies, the subsequent ability of these
immune complexes to activate immune cells via receptor binding,
and the potency of the allergen to induce inflammatory reactions
in vivo. The specific results would not have been predicted by a
priori geometric analyses of the anticipated immune complexes
resulting from IgE binding to the various molecular constructs
investigated. Using negative-stain EM for the visualization of
immune complexes, it could be shown that antigens containing
epitopes placed in adjacent positions (ie, the 2 constructs with
2N epitopes) resulted in a greater proportion of closed ring
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antigens containing IgE epitopes in distant positions (ie, toward
opposite side of the antigen) mainly formed open chain immune
complexes. As early as the 1960s, Valentine and Green34 used
negative-stain EM to show an abundance of dimer rings in an
antibody-divalent hapten-carrier model reaction. In this example,
the 2 hapten epitopes were located on opposite sides of the carrier.
Later, negative-stain EM was used to show that the relative
locations of epitope pairs can have a significant effect on the
formation of rings versus chains in an idiotype-anti-idiotype
immune complex system.35 However, our study is the first to
demonstrate that the formation of different immune complex
shapes is related to the proximity of the epitopes on a traditional
antigen. The hinge-mediated rotational flexibility of the antibody
Fab arms plays an important role in facilitating or inhibiting dimer
ring formation, especially in systems with inflexible epitopes.
Because IgE lacks a formal hinge region and its Fab arms
display slower rates of segmental motion,36 an interesting
potential explanation for the lack of ring forms in some of the
divalent constructs is the inability of the Fab arms of IgE to
freely rotate around their long axis to accommodate the fixed
positions and orientations of some of the epitopes in some
constructs. Although IgE does show considerable hinge-like
(bending) flexibility, which can result in IgE Fab arm
orientations ranging from ‘‘T’’-like to near parallel orientation,32
the relative ability of IgE Fab arms to rotate has not been
established.
The accessibility and the relative position of the engineered
epitopes in the 3-dimensional structure of the constructs is
unknown. Nevertheless, results from negative-stain EM support
that the epitopes are accessible and in relative positions that differ
depending on the design of the construct. Furthermore, we think
that negative-stain EM for visualization of antibody-antigen
complexes has an advantage over cocrystallization, which
requires a homogeneous preparation of each complex, and is
performed under nonphysiological antigen/antibody concentra-
tions. In fact, the data were indeed in good agreement with the
biological experiments.
Artificial allergen constructs containing epitopes engineered
into adjacent positions were more potent in activating effector
cells of allergy in vitro and inducing allergic reactions in vivo
using a murine model for anaphylaxis. This effect was most
evident at low allergen concentrations, which probably reflect
the more clinically relevant situation in patients who normally
are exposed to very low quantities of allergens. Our data thus
provide a novel explanation for the long sought question: ‘‘Why
are certain allergens more potent than others.’’ In fact, our study
is the first to demonstrate that not only the number of epitopes
but also their proximity determines the allergenic activity of an
allergenmolecule.We are aware that respiratory allergens contain
mainly conformational epitopes37 but think that the findingsmade
with the grafted sequential epitopes also apply for conformational
epitopes because the latter ones also can occur in different
proximity. It must also be borne in mind that the IgE response
of allergic patients is polyclonal24 and that the IgE antibodies in
such a polyclonal response may have different affinities to the
corresponding allergen,38 which will affect allergenic activity.
However, studies using defined reagents such as ours are needed
to study the contribution of each of the different factors (ie, IgE
levels, number of IgE epitopes, proximity, affinity, polyclonality)
to allergenic activity.Furthermore, we confirmed by in vivo experiments that
increases in allergen-specific IgE levels lead to stronger allergic
reactions, which is in agreement with in vitro results obtained
with chemically cross-linked epitopes.16 This finding provides
an explanation as to why allergic patients, who have increased
allergen-specific IgE levels after allergen exposure, become
more sensitive to the allergen and show stronger allergic reactions
and increased basophil degranulation.39,40
In summary, our results define key parameters that dictate the
extent of immediate type inflammatory reactions in allergy
induced by allergen-IgE immune complexes. Importantly, they
reveal a hitherto unknown effect of the proximity of antibody
binding sites on an allergen on the shape of resulting immune
complexes and the subsequent activation of Fc receptor-bearing
effector cells in in vitro and in vivo models of allergy. We believe
that this result is novel and important for several reasons. First, it
sheds light on the as yet not fully resolved question of what factors
determine the potency (ie, allergenic activity) of an allergen
molecule. Second, it may be possible to use the knowledge, that
IgE epitopes located in more distant proximity reduce the potency
of allergens, for the engineering of safer allergy vaccines that
induce less severe allergenic adverse effects upon administration
to sensitized patients. It is also quite possible that the results
obtained from our artificial allergen-IgE model system may
well be generally applicable to immune complexes containing
other mmunoglobulin classes and other disease-relevant antigens.
In this context, one may consider classical immune complex–
mediated diseases, such as systemic lupus erythematosus, farmers
lung, and classical serum sickness, to name a few. However, our
findings may also be important for type II hypersensitivity
diseases that involve mechanisms such as antibody-dependent
cellular cytotoxicity, which are important in various autoimmune
diseases, such as idiopathic thrombocytopenic purpura, Graves
disease, and myasthenia gravis and in defense against cancer as
well as infectious agents.
In this context, it is tempting to speculate that by positioning of
binding sites on receptor binding molecules (ie, ligands), it may
be possible to engineer a new class of immunomodulatory
molecules for the treatment of various immunologically mediated
diseases, such as allergies, autoimmune diseases, cancer,
infectious diseases, and immune deficiencies.
Clinical implications: The demonstration that the proximity of
IgE epitopes affects the allergenic activity of an allergen iden-
tifies a hitherto unknown determinant of the allergenic potency
of allergens and may be useful for the rational design of allergy
vaccines.REFERENCES
1. Nimmerjahn F, Ravetch JV. Antibody-mediated modulation of immune responses.
Immunol Rev 2010;236:265-75.
2. W€uthrich B, Schindler C, Leuenberger P, Ackermann-Liebrich U. Prevalence of
atopy and pollinosis in the adult population of Switzerland (SAPALDIA study).
Swiss Study on Air Pollution and Lung Diseases in Adults. Int Arch Allergy
Immunol 1995;106:149-56.
3. Holgate ST. Innate and adaptive immune responses in asthma. Nat Med 2012;18:
673-83.
4. Wills-Karp M, Ewart SL. Time to draw breath: asthma-susceptibility genes are
identified. Nat Rev Genet 2004;5:376-87.
5. Bischoff SC. Role of mast cells in allergic and non-allergic immune responses:
comparison of human and murine data. Nat Rev Immunol 2007;7:93-104.
6. Dombrowicz D, Capron M. Eosinophils, allergy and parasites. Curr Opin Immunol
2001;13:716-20.
J ALLERGY CLIN IMMUNOL
VOLUME 137, NUMBER 5
GIERAS ET AL 15657. Gould HJ, Sutton BJ. IgE in allergy and asthma today. Nat Rev Immunol 2008;8:
205-17.
8. Galli SJ, Tsai M. IgE and mast cells in allergic disease. Nat Med 2012;18:693-704.
9. Landsteiner K. Experiments on anaphylaxis to azoproteins. J Exp Med 1924;39:
631-7.
10. Lichtenstein LM, Osler AG. Studies on the mechanisms of hypersensitivity
phenomena, IX: histamine release from human leukocytes by ragweed pollen
antigen. J Exp Med 1964;120:507-30.
11. Segal DM, Taurog JD, Metzger H. Dimeric immunoglobulin E serves as a unit
signal for mast cell degranulation. Proc Natl Acad Sci U S A 1977;74:2993-7.
12. Fewtrell C, Metzger H. Larger oligomers of IgE are more effective than dimers in
stimulating rat basophilic leukemia cells. J Immunol 1980;125:701-10.
13. Kagey-Sobotka A, Dembo M, Goldstein B, Metzger H, Lichtenstein LM.
Qualitative characteristics of histamine release from human basophils by
covalently cross-linked IgE. J Immunol 1981;127:2285-91.
14. Marone G, Kagey-Sobotka A, Lichtenstein LM. IgE-mediated histamine release
from human basophils: differences between antigen E- and anti-IgE-induced
secretion. Int Arch Allergy Appl Immunol 1981;65:339-48.
15. Valenta R, Ferreira F, Focke-Tejkl M, Linhart B, Niederberger V, Swoboda I, et al.
From allergen genes to allergy vaccines. Annu Rev Immunol 2010;28:211-41.
16. Gieras A, Focke-Tejkl M, Ball T, Verdino P, Hartl A, Thalhamer J, et al. Molecular
determinants of allergen-induced effector cell degranulation. J Allergy Clin
Immunol 2007;119:384-90.
17. Greene WK, Thomas WR. IgE binding structures of the major house dust mite
allergen Der p I. Mol Immunol 1992;29:257-62.
18. Ball T, Vrtala S, Sperr WR, Valent P, Susani M, Kraft D, et al. Isolation of an
immunodominant IgE hapten from an epitope expression cDNA library: dissection
of the allergic effector reaction. J Biol Chem 1994;269:28323-8.
19. Fedorov AA, Ball T, Mahoney NM, Valenta R, Almo SC. The molecular basis for
allergen cross-reactivity: crystal structure and IgE-epitope mapping of birch pollen
profilin. Structure 1997;5:33-45.
20. Shin DS, Compadre CM, Maleki SJ, Kopper RA, Sampson H, Huang SK, et al.
Biochemical and structural analysis of the IgE binding sites on Ara h1, an abundant
and highly allergenic peanut protein. J Biol Chem 1998;273:13753-9.
21. Flicker S, Steinberger P, Ball T, Krauth MT, Verdino P, Valent P, et al. Spatial
clustering of the IgE epitopes on the major timothy grass pollen allergen Phl p 1:
importance for allergenic activity. J Allergy Clin Immunol 2006;117:1336-43.
22. Padavattan S, Flicker S, Schirmer T, Madritsch C, Randow S, Reese G, et al.
High-affinity IgE recognition of a conformational epitope of the major respiratory
allergen Phl p 2 as revealed by X-ray crystallography. J Immunol 2009;182:
2141-51.
23. Hochwallner H, Schulmeister U, Swoboda I, Focke-Tejkl M, Civaj V, Balic N,
et al. Visualization of clustered IgE epitopes on alpha-lactalbumin. J Allergy
Clin Immunol 2010;125:1279-85.e9.24. Levin M, Rydnert F, K€allstr€om E, Tan LW, Wormald PJ, Lindstedt M, et al. Phl p
1-specific human monoclonal IgE and design of a hypoallergenic group 1 grass
pollen allergen fragment. J Immunol 2013;191:551-60.
25. Focke M, Mahler V, Ball T, Sperr WR, Majlesi Y, Valent P, et al. Nonanaphylactic
synthetic peptides derived from B cell epitopes of the major grass pollen allergen,
Phl p 1, for allergy vaccination. FASEB J 2001;15:2042-4.
26. Laemmli UK. Cleavage of structural proteins during the assembly of the head of
bacteriophage T4. Nature 1970;227:680-5.
27. Valenta R, Duchene M, Pettenburger K, Sillaber C, Valent P, Bettelheim P, et al.
Identification of profilin as a novel pollen allergen: IgE autoreactivity in sensitized
individuals. Science 1991;253:557-60.
28. Roux KH. Negative-stain immunoelectron-microscopic analysis of small
macromolecules of immunologic significance. Methods 1996;10:247-56.
29. Eccleston E, Leonard BJ, Lowe JS, Welford HJ. Basophilic leukaemia in the albino
rat and a demonstration of the basopoietin. Nat New Biol 1973;244:73-6.
30. Khodoun MV, Strait R, Armstrong L, Yanase N, Finkelman FD. Identification of
markers that distinguish IgE- from IgG-mediated anaphylaxis. Proc Natl Acad
Sci U S A 2011;108:12413-8.
31. Evans SV, Brayer GD. Horse heart metmyoglobin: a 2.8-A resolution
three-dimensional structure determination. J Biol Chem 1988;263:4263-8.
32. Roux KH, Strelets L, Brekke OH, Sandlie I, Michaelsen TE. Comparisons of the
ability of human IgG3 hinge mutants, IgM, IgE, and IgA2, to form small immune
complexes: a role for flexibility and geometry. J Immunol 1998;161:4083-90.
33. Epstein MM. Do mouse models of allergic asthma mimic clinical disease? Int Arch
Allergy Immunol 2004;133:84-100.
34. Valentine RC, Green NM. Electron microscopy of an antibody-hapten complex.
J Mol Biol 1967;27:615-7.
35. Roux KH, Monafo WJ, Davie JM, Greenspan NS. Construction of an
extended three-dimensional idiotope map by electron microscopic analysis of
idiotope-anti-idiotope complexes. Proc Natl Acad Sci U S A 1987;84:4984-8.
36. Holowka D, Wensel T, Baird B. A nanosecond fluorescence depolarization study
on the segmental flexibility of receptor-bound immunoglobulin E. Biochemistry
1990;29:4607-12.
37. Valenta R, Kraft D. Recombinant allergen molecules: tools to study effector cell
activation. Immunol Rev 2001;179:119-27.
38. Willumsen N, Holm J, Christensen LH, W€urtzen PA, Lund K. The complexity
of allergic patients’ IgE repertoire correlates with serum concentration of
allergen-specific IgE. Clin Exp Allergy 2012;42:1227-36.
39. Lichtenstein LM, Ishizaka K, Norman PS, Sobotka AK, Hill BM. IgE antibody
measurements in ragweed hay fever: relationship to clinical severity and the results
of immunotherapy. J Clin Invest 1973;52:472-82.
40. Niederberger V, Ring J, Rakoski J, Jager S, Spitzauer S, Valent P, et al.
Antigens drive memory IgE responses in human allergy via the nasal mucosa.
Int Arch Allergy Immunol 2007;142:133-44.
